Evidence map›Paper›PMID 35937289›Full record

ArticleFrontiers in veterinary science2022

Antitumor Effects of Cannabinoids in Human Pancreatic Ductal Adenocarcinoma Cell Line (Capan-2)-Derived Xenograft Mouse Model.

Siriwan Sakarin, Nuntana Meesiripan, Suleeporn Sangrajrang, Nuntakan Suwanpidokkul, Piyaporn Prayakprom, Chatchada Bodhibukkana, Vipada Khaowroongrueng, Kankanit Suriyachan, Somchai Thanasittichai, Attasit Srisubat and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in veterinary science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Frontiers in pharmacology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Siriwan SakarinDivision of Research and Academic Support, National Cancer Institute, Bangkok, Thailand.
Nuntana MeesiripanDivision of Research and Academic Support, National Cancer Institute, Bangkok, Thailand.
Suleeporn SangrajrangDivision of Research and Academic Support, National Cancer Institute, Bangkok, Thailand.
Nuntakan SuwanpidokkulThe Government Pharmaceutical Organization, Bangkok, Thailand.
Piyaporn PrayakpromThe Government Pharmaceutical Organization, Bangkok, Thailand.
Chatchada BodhibukkanaThe Government Pharmaceutical Organization, Bangkok, Thailand.
Vipada KhaowroongruengThe Government Pharmaceutical Organization, Bangkok, Thailand.
Kankanit SuriyachanInstitute of Medical Research and Technology Assessment, Ministry of Public Health, Nonthaburi, Thailand.
Somchai ThanasittichaiInstitute of Medical Research and Technology Assessment, Ministry of Public Health, Nonthaburi, Thailand.
Attasit SrisubatDivision of Medical Technical and Academic Affairs, Ministry of Public Health, Nonthaburi, Thailand.
Pattamaporn SurawongsinResearch and Technology Assessment Department, Ophthalmology Department, Lerdsin Hospital, Bangkok, Thailand.
Kasem RattanapinyopitukCenter of Excellent for Companion Animal Cancer, Department of Veterinary Pathology, Faculty of Veterinary Science, Chulalongkorn University, Bangkok, Thailand.
Government of Thailand · THNational Cancer Institute of Thailand · THMinistry of Public Health · THChulalongkorn University · THHealth Intervention and Technology Assessment Program · THLerdsin Hospital · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Pancreatic cancer is considered a rare type of cancer, but the mortality rate is high. Cannabinoids extracted from the cannabis plant have been interested as an alternative treatment in cancer patients. Only a few studies are available on the antitumor effects of cannabinoids in pancreatic cancer. Therefore, this study aims to evaluate the antitumor effects of cannabinoids in pancreatic cancer xenografted mouse model. Materials and Methods: Twenty-five nude mice were subcutaneously transplanted with a human pancreatic ductal adenocarcinoma cell line (Capan-2). All mice were randomly assigned into 5 groups including negative control (gavage with sesame oil), positive control (5 mg/kg 5-fluorouracil intraperitoneal administration), and cannabinoids groups that daily received THC:CBD, 1:6 at 1, 5, or 10 mg/kg body weight for 30 days, respectively. Xenograft tumors and internal organs were collected for histopathological examination and immunohistochemistry. Results: The average tumor volume was increased in all groups with no significant difference. The average apoptotic cells and caspase-3 positive cells were significantly increased in cannabinoid groups compared with the negative control group. The expression score of proliferating cell nuclear antigen in positive control and cannabinoids groups was decreased compared with the negative control group. Conclusions: Cannabinoids have an antitumor effect on the Capan-2-derived xenograft mouse model though induce apoptosis and inhibit proliferation of tumor cells in a dose-dependent manner.

Indexed as

cannabinoidsCapan-2mousepancreatic cancerxenograft tumor model

Identifiers

PMID35937289
PMCPMC9353045
OpenAlexW4286447690

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.